Amlodipine/chlorthalidone/telmisartan- Addpharma
Alternative Names: AD-209; telmisartan 20 mg/amlodipine 2.5 mg/chlorthalidone 6.25 mgLatest Information Update: 04 Dec 2025
At a glance
- Originator Addpharma
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Essential hypertension
Most Recent Events
- 29 Aug 2025 Efficacy and adverse events data from a phase III trial in Essential hypertension presented at the ESC Congress 2025 - Annual Congress of the European Society of Cardiology together with World Congress of Cardiology (ESCWCC-2025)
- 19 Sep 2024 Efficacy and adverse events data from a phase II trial in Essential hypertension presented at the the International Society of Hypertension (ISH-2024)
- 20 May 2024 Phase-III clinical trials in Essential hypertension in South Korea (PO) (NCT06348576)